Evidence map›Paper›PMID 36319728›Full record

SynthesisScientific reports2022

Association between metabolic syndrome and uric acid: a systematic review and meta-analysis.

Elena Raya-Cano, Manuel Vaquero-Abellán, Rafael Molina-Luque, Domingo De Pedro-Jiménez, Guillermo Molina-Recio, Manuel Romero-Saldaña

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Effect of Celery Seed (Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Elena Raya-CanoDepartment of Nursing, Pharmacology and Physiotherapy, University of Córdoba, Córdoba, Spain.
Manuel Vaquero-AbellánDepartment of Nursing, Pharmacology and Physiotherapy, University of Córdoba, Córdoba, Spain.
Rafael Molina-LuqueDepartment of Nursing, Pharmacology and Physiotherapy, University of Córdoba, Córdoba, Spain. p72molur@uco.es.
Domingo De Pedro-JiménezFaculty of Nursing, University of Cádiz, Cádiz, Spain.
Guillermo Molina-RecioDepartment of Nursing, Pharmacology and Physiotherapy, University of Córdoba, Córdoba, Spain.
Manuel Romero-SaldañaDepartment of Nursing, Pharmacology and Physiotherapy, University of Córdoba, Córdoba, Spain.
Instituto Maimónides de Investigación Biomédica de Córdoba · ESUniversity of Córdoba · ESBiomedical Research Institute · USUniversidad de Cádiz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This systematic review and meta-analysis aim to provide the best evidence on the association between metabolic syndrome (MetS) and uric acid (UA) by determining the size of the effect of this biomarker on MetS. The review protocol is registered with PROSPERO (CRD42021231124). The search covered the PubMed and Scopus databases. Methodological quality was assessed with the STROBE tool, overall risk of bias with RevMan (Cochrane Collaboration) and quality of evidence with Grade Pro. Initially, 1582 articles were identified. Then, after excluding duplicates and reviewing titles and abstracts, 1529 articles were excluded from applying the eligibility criteria. We included 43 papers (56 groups) comparing UA concentrations between subjects 91,845 with MetS and 259,931 controls. Subjects with MetS had a higher mean UA of 0.57 mg/dl (95% CI 0.54-0.61) (p < 0.00001). Given the heterogeneity of the included studies, the researchers decided to perform subgroups analysis. Men with MetS have a higher UA concentration mg/dl 0.53 (95% CI 0.45-0.62, p < 0.00001) and women with MetS 0.57 (95% CI 0.48-0.66, p < 0.00001) compared to subjects without MetS. Assessment of UA concentration could provide a new avenue for early diagnosis of MetS, as a new biomarker and the possibility of new therapeutic targets.

Indexed as

Metabolic SyndromeUric AcidBiomarkersFemaleHumansMaleBiomarkersUric Acid

Identifiers

PMID36319728
PMCPMC9626571
OpenAlexW4308147079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.